Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

Sarcopenia is a muscle loss syndrome known as a risk factor of various carcinomas. The impact of sarcopenia and sarcopenia-related inflammatory/nutritional markers in metastatic urothelial carcinoma (mUC) treated with pembrolizumab was unknown, so this retrospective study of 27 patients was performe...

Full description

Bibliographic Details
Main Authors:	Takuto Shimizu, Makito Miyake, Shunta Hori, Kazuki Ichikawa, Chihiro Omori, Yusuke Iemura, Takuya Owari, Yoshitaka Itami, Yasushi Nakai, Satoshi Anai, Atsushi Tomioka, Nobumichi Tanaka, Kiyohide Fujimoto
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Diagnostics
Subjects:	immune checkpoint inhibitor Pembrolizumab Sarcopenia psoas muscle mass index neutrophil-to-lymphocyte ratio prognostic nutritional index
Online Access:	https://www.mdpi.com/2075-4418/10/5/310

Similar Items

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
by: Takuto Shimizu, et al.
Published: (2022-03-01)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
by: Hiroyuki Nishiyama, et al.
Published: (2023-06-01)

Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
by: Naoto Iwai, et al.
Published: (2021-07-01)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
by: Yousuke Fukiishi, et al.
Published: (2023-03-01)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
by: Yung-Hao Liu, et al.
Published: (2021-09-01)

The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma
by: Risa Tomioka-Inagawa, et al.
Published: (2022-07-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
by: Katsuhiro Ito, et al.
Published: (2023-02-01)

A comprehensive investigation of nutritional status and psoas muscle mass in predicting five-year survival in patients with liver transplant
by: Ya-Tzu Tsao, et al.
Published: (2022-07-01)

Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma
by: Takuto Shimizu, et al.
Published: (2020-03-01)

Reply to “Predictors of Recurrence for T3a RCC: A Recurring Conundrum”
by: Makito Miyake, et al.
Published: (2020-11-01)

Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
by: Makito Miyake, et al.
Published: (2020-07-01)

Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report
by: Yasumiko Jodai, et al.
Published: (2023-01-01)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022-10-01)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
by: Giulio Rizzetto, et al.
Published: (2023-08-01)

Pembrolizumab-Induced Nasal Polyposis: The First Reported Case
by: Justin M. Hintze, et al.
Published: (2023-07-01)

Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)

Poor preoperative enteral nutrition would be a risk factor for readmission due to infection after liver transplantation
by: Kyung Won Seo, et al.
Published: (2020-03-01)

Psoas Muscle Index – Could It Be an Indicator of Postoperative Complications in Colorectal Cancer? Case Presentation and Review of the Literature
by: Scurtu Georgiana Alexandra, et al.
Published: (2022-12-01)

Low preoperative psoas muscle mass index is a risk factor for distal cholangiocarcinoma recurrence after pancreatoduodenectomy: a retrospective analysis
by: Saori Umezawa, et al.
Published: (2022-06-01)

Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab
by: Karla Lauš, et al.
Published: (2023-01-01)

Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma
by: Miyake M, et al.
Published: (2018-12-01)

Based on CT at the third lumbar spine level, the skeletal muscle index and psoas muscle index can predict osteoporosis
by: Cheng-bin Huang, et al.
Published: (2022-10-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
by: Makito Miyake, et al.
Published: (2023-01-01)

The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors
by: Wei Sun, et al.
Published: (2024-04-01)

Low Psoas Lumbar Vertebral Index Is Associated with Mortality after Hip Fracture Surgery in Elderly Patients: A Retrospective Analysis
by: Ji-Hoon Sim, et al.
Published: (2021-07-01)

Psoas Muscle Index Defined by Computer Tomography Predicts the Presence of Postoperative Complications in Colorectal Cancer Surgery
by: Zalán Benedek, et al.
Published: (2021-05-01)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
by: Yen-Hao Chen, et al.
Published: (2023-08-01)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
by: Noemí Puig, et al.
Published: (2020-12-01)

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
by: Blaine Brower, et al.
Published: (2024-04-01)

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
by: Toyohiro Yamada, et al.
Published: (2022-09-01)

Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method
by: Makito Miyake, et al.
Published: (2021-01-01)

Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer
by: Yusuke Iemura, et al.
Published: (2023-12-01)

Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma
by: Makito Miyake, et al.
Published: (2020-10-01)

Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab
by: El-ghazzi N, et al.
Published: (2023-06-01)

Pembrolizumab induced pericardial tamponade: A case report
by: Dariusz Uczkowski, et al.
Published: (2023-05-01)

Molecular Farming of Pembrolizumab and Nivolumab
by: Michael C. Stark, et al.
Published: (2023-06-01)

Psoas abscess secondary to atypical appendicitis in pregnancy. A case report
by: Viviana de la Caridad Sáez Cantero, et al.
Published: (2023-10-01)